Robatumumab
Based on 1 Customer Validation
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.00%
- CAS No.: 934235-44-6
- Masse moléculaire:146.36 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1(D356E/L358M) kappa
Human
IGF1R/CD221
Robatumumab (0.02-80 nM; 0.5 or 4 h) downregulates IGF-IR and inhibits both basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SK-N-FI cells
-
Concentration:0.02-80 nM
-
Incubation Time:0.5 or 4 hours
-
Result:Inhibited the IGF-I–stimulated phosphorylation of IGF-IR after treatment 0.5 h.
Resulted in both inhibition of IGF-IR phosphorylation and receptor downregulation after treatment 4 h.
Resulted in a dose-dependent inhibition of the IGF-I–stimulated IRS-1 phosphorylation.
Robatumumab (intravenous injection; 0.02-0.5 mg/mouse; twice weekly; 35 d) inhibits the osteosarcoma growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 d) inhibits the SJCRH30 and RD rhabdomyosarcoma cell growth in xenograft model[2].
Robatumumab (intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 w) blocks effectively pediatric tumor cell proliferation in vivo[2].
Robatumumab (intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation) modulates the blood vessel formation via its antiangiogenesis effect[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice inoculated with SK-N-FI tumor cells[2]
-
Dosage:0.04 or 0.1 mg/mouse
-
Administration:Intravenous injection; 0.04 or 0.1 mg/mouse; twice weekly; 18 days
-
Result:Inhibited the SK-N-FI xenograft tumor by 96% in the 0.04 mg dose group and resulted in 11% tumor regression in the 0.1 mg dose group.
-
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma[2]
-
Dosage:0.02, 0.1 or 0.5 mg/mouse
-
Administration:Intravenous injection; 0.02, 0.1 or 0.5 mg/mouse; twice weekly; 35 days
-
Result:Inhibited the tumor growth by 71%, 82%, and 88% at 0.02, 0.1, and 0.5 mg, respectively, at day 14 after treatment.
-
Animal Model:Nude mice inoculated with SJCRH30 and RD rhabdomyosarcoma cells[2]
-
Dosage:0.1 or 0.5 mg/mouse
-
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 14 days
-
Result:Inhibited tumor growth by 39% and 58% at 0.1 and 0.5 mg dose, respectively, in the RD rhabdomyosarcoma model.
Inhibited tumor growth by 37% and 53% at 0.1 and 1 mg dose, respectively, in the SJCRH30 model.
-
Animal Model:Nude mice inoculated with SK-N-FI neuroblastoma and SJSA-1 osteosarcoma[2]
-
Dosage:0.1 or 0.5 mg/mouse
-
Administration:Intravenous injection; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks
-
Result:Reduced the tumor Ki-67 staining by 38% and along with significant change in SK-N-FI neuroblastoma xenograft.
Reduced the staining of Ki-67 by 37% and 51% after 0.1 and 0.5 mg SCH 717454 treatment, respectively, in the SJSA-1 osteosarcoma xenograft.
-
Animal Model:Nude mice inoculated with SJSA-1 osteosarcoma[2]
-
Dosage:0.5 mg/mouse
-
Administration:Intravenous injection; 0.5 mg/mouse; once; day 11 post-inoculation
-
Result:Reduced in the intensity of the fluorescent lectin staining by 74% at 0.5 mg dose, showing thinner blood vessels and reduced branches, compared with control IgG1.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 MCF-7 cells with Robatumumab (HY-P99218, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1(E356D/M358L) kappa (HY-P990100, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 934235-44-6
-
Appearance Liquid
-
Masse moléculaire 146.36 kDa
-
Color Colorless to light yellow
-
SMILES
[Robatumumab]
-
Synonyms
Sch 717454; 19D12
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Anderson PM, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 2016 Oct;63(10):1761-70. [Content Brief]
[2]. Wang Y, et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. Mol Cancer Ther. 2010 Feb;9(2):410-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Robatumumab Related Classifications
HY-P99218 Related Classifications
Powered by Bioz